What Happened
In August 2026, Ascletis Pharma initiated two US Phase 1 studies after the FDA cleared its Investigational New Drug applications. Among the programs is ASC36, a long-acting amylin receptor peptide agonist. The launch marks the company's entry into US clinical testing for its metabolic candidates and adds to the widening field of amylin-directed research.
What ASC36 Is
ASC36 is a long-acting amylin receptor peptide agonist. It targets the amylin receptor, a pathway distinct from the GLP-1 signaling that anchors most established obesity therapeutics. Amylin signaling contributes a separate satiety mechanism, and the long-acting design is intended to support extended dosing intervals. As a peptide directed specifically at the amylin receptor, ASC36 belongs to a class that has moved from a supporting role to central interest in recent obesity research, as investigators test what the amylin pathway can contribute on its own and in combination.
The Regulatory Step
The studies began after FDA clearance of Ascletis's IND applications. IND clearance is the regulatory gate that permits human testing to start in the United States, so the clearance and the study launch together mark the transition from preclinical work to clinical evaluation. Two Phase 1 studies opening in parallel reflect an effort to advance the program on more than one front at once, rather than sequentially. That parallel approach can accelerate early development, though each study still has to establish safety and tolerability on its own terms.
Amylin Momentum
ASC36's arrival reflects broad momentum in the amylin class. That class now includes several notable efforts: petrelintide, Zealand Pharma's once-weekly amylin analogue; amycretin, Novo Nordisk's GLP-1/amylin single molecule; and cagrilintide, the amylin component of Novo Nordisk's CagriSema combination. ASC36 adds another entrant to a field that has expanded considerably as researchers probe amylin's potential. The recurring interest across these programs is in what amylin signaling might offer, including questions about tolerability and lean-mass preservation that are being explored in the more advanced amylin candidates.
As Phase 1 studies, the ASC36 programs are focused on safety, tolerability, and early pharmacology. There are no efficacy outcomes to report at this stage, and none should be expected from first-in-human work. The value of the milestone lies in adding a differentiated amylin candidate to US clinical development and in expanding the range of amylin-directed compounds being tested. Whether ASC36 progresses will depend on the early-stage data it is designed to produce.
What It Means
The ASC36 launch is a marker of how crowded and active the amylin space has become. With multiple companies advancing amylin-directed peptides, the class is being tested from several angles at once, including amylin-alone approaches and combinations with GLP-1. Ascletis's entry broadens that exploration and reinforces the sense that amylin has become one of the more closely studied targets in obesity research.
Important Note
This article is for educational and research reference purposes only. It does not provide dosing advice for human use. Peptide compounds discussed here are sold for research purposes, and nothing here constitutes medical advice. Approved medications should only be used under physician supervision.